SCHEDULE 13G/A 0000921895-22-003221 0000918923 XXXXXXXX LIVE 1 Common Shares, par value CHF 0.05 10/31/2025 0001783036 NewcelX Ltd. H5835A109 THE CIRCLE 6 ZURICH V8 8058 Rule 13d-1(c) BIOTECHNOLOGY VALUE FUND L P a DE 0.00 15196.00 0.00 15196.00 15196.00 N 0.3 PN BVF I GP LLC a DE 0.00 15196.00 0.00 15196.00 15196.00 N 0.3 OO BIOTECHNOLOGY VALUE FUND II LP a DE 0.00 11746.00 0.00 11746.00 11746.00 N 0.3 PN BVF II GP LLC a DE 0.00 11746.00 0.00 11746.00 11746.00 N 0.3 OO Biotechnology Value Trading Fund OS LP a E9 0.00 1334.00 0.00 1334.00 1334.00 N 0.03 PN BVF Partners OS Ltd. a E9 0.00 1334.00 0.00 1334.00 1334.00 N 0.03 CO BVF GP HOLDINGS LLC a DE 0.00 26942.00 0.00 26942.00 26942.00 N 0.6 OO BVF PARTNERS L P/IL a DE 0.00 28732.00 0.00 28732.00 28732.00 N 0.6 IA PN BVF INC/IL a DE 0.00 28732.00 0.00 28732.00 28732.00 N 0.6 CO LAMPERT MARK N a X1 0.00 28732.00 0.00 28732.00 28732.00 N 0.6 IN NewcelX Ltd. THE CIRCLE 6, ZURICH, SWITZERLAND 8058 Biotechnology Value Fund, L.P. ("BVF") BVF I GP LLC ("BVF GP") Biotechnology Value Fund II, L.P. ("BVF2") BVF II GP LLC ("BVF2 GP") Biotechnology Value Trading Fund OS LP ("Trading Fund OS") BVF Partners OS Ltd. ("Partners OS") BVF GP Holdings LLC ("BVF GPH") BVF Partners L.P. ("Partners") BVF Inc. Mark N. Lampert ("Mr. Lampert") Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons." Biotechnology Value Fund, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF I GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Fund II, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF II GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Trading Fund OS LP PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF Partners OS Ltd. PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF GP Holdings LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Partners L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Inc. 44 Montgomery St., 40th Floor San Francisco, California 94104 Mark N. Lampert 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Fund, L.P. Delaware BVF I GP LLC Delaware Biotechnology Value Fund II, L.P. Delaware BVF II GP LLC Delaware Biotechnology Value Trading Fund OS LP Cayman Islands BVF Partners OS Ltd. Cayman Islands BVF GP Holdings LLC Delaware BVF Partners L.P. Delaware BVF Inc. Delaware Mark N. Lampert United States Y As of the close of business on November 4, 2025, the Reporting Persons and a certain Partners managed account (the "Partners Managed Account") hold pre-funded warrants (the "Pre-Funded Warrants") exercisable for an aggregate of 14,366 Shares. As of the close of business on November 4, 2025, (i) BVF beneficially owned 15,196 Shares, including 7,598 Shares underlying the Pre-Funded Warrants held by it, (ii) BVF2 beneficially owned 11,746 Shares, including 5,873 Shares underlying the Pre-Funded Warrants held by it, and (iii) Trading Fund OS beneficially owned 1,334 Shares, including 667 Shares underlying the Pre-Funded Warrants held by it. BVF GP, as the general partner of BVF, may be deemed to beneficially own the 15,196 Shares beneficially owned by BVF. BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 11,746 Shares beneficially owned by BVF2. Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 1,334 Shares beneficially owned by Trading Fund OS. BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 26,942 Shares beneficially owned in the aggregate by BVF and BVF2. Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 28,732 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, including 456 Shares held in the Partners Managed Account, which includes 228 Shares underlying the Pre-Funded Warrants held in the Partners Managed Account. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 28,732 Shares beneficially owned by Partners. Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 28,732 Shares beneficially owned by BVF Inc. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities. The following percentages are based upon a denominator that is the sum of: (i) 4,558,378 Shares outstanding as of October 31, 2025, which is the total number of Shares outstanding as reported in the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on October 29, 2025, and (ii) 14,366 Shares issuable upon the exercise of the Pre-Funded Warrants owned by the Reporting Persons and the Partners Managed Account. As of the close of business on November 4, 2025, (i) BVF, BVF 2 and Trading Fund OS beneficially owned less than 1% of the outstanding Shares and (ii) BVF GP, BVF2 GP, Partners OS, BVF GPH, Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own less than 1% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account). See Cover Pages Items 5-9. See Cover Pages Items 5-9. See Cover Pages Items 5-9. See Cover Pages Items 5-9. N Y Y Y N See Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on December 16, 2022. Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. BIOTECHNOLOGY VALUE FUND L P /s/ Mark N. Lampert 11/04/2025 BVF I GP LLC /s/ Mark N. Lampert 11/04/2025 BIOTECHNOLOGY VALUE FUND II LP /s/ Mark N. Lampert 11/04/2025 BVF II GP LLC /s/ Mark N. Lampert 11/04/2025 Biotechnology Value Trading Fund OS LP /s/ Mark N. Lampert 11/04/2025 BVF Partners OS Ltd. /s/ Mark N. Lampert 11/04/2025 BVF GP HOLDINGS LLC /s/ Mark N. Lampert 11/04/2025 BVF PARTNERS L P/IL /s/ Mark N. Lampert 11/04/2025 BVF INC/IL /s/ Mark N. Lampert 11/04/2025 LAMPERT MARK N /s/ Mark N. Lampert 11/04/2025